StockNews.AI
EBS
StockNews.AI
154 days

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

1. EBS secures $27M in international orders for medical countermeasures in 2025. 2. Orders address smallpox and anthrax threats, enhancing global health security. 3. CEO emphasizes international expansion and preparedness commitments. 4. Emergent focuses on national security and public health responses. 5. Company leverages 25 years of expertise in life-saving solutions.

4m saved
Insight
Article

FAQ

Why Bullish?

The $27M contracts indicate robust demand for EBS’s products, improving revenue outlook. Historical trends show that significant contracts often lead to increased investor interest and stock appreciation.

How important is it?

The announcement of new international orders underlines EBS’s growth potential and capability in a critical sector, making it highly relevant for investors.

Why Short Term?

Orders are set for delivery in 2025, providing immediate revenue visibility. Short-term stock movements often react positively to contract announcements.

Related Companies

VNDABAXAMRX
GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for delivery in 2025 associated with its medical countermeasures (MCM) portfolio. These orders will help address potential threats of smallpox and anthrax and will contribute to the overall supply of MCM’s to the international market in 2025. “Emergent is a trusted partner to supply communities around the world with medical countermeasures that protect against serious health threats like smallpox and anthrax,” said Joe Papa, president and CEO of Emergent. “We are pleased to engage and support global partners in fulfilling their preparedness needs. As part of our multi-year transformation plan, we will continue to focus on international expansion efforts and strengthening health preparedness at home and abroad.” Emergent specializes in developing, manufacturing, and supplying MCMs for national security and public health preparedness. These products enable governments to effectively respond to emergencies and protect the public from potential threats. The types and quantities of products that should be maintained in a stockpile will depend on the population requiring protection, the products available for meeting the threat, as well as government resources and priorities. About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com

Related News